WILEX is a biopharmaceutical company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich.

WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malignant tumours in the body.

The late stage multi-product portfolio includes both drug and medicinal product candidates as well as research candidates.

Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The company’s strategy is to develop WILEX into a commercially successful biopharmaceutical company with a broad portfolio of new drugs and medical products for the treatment of cancer.